Salivary proteomics for oral cancer biomarker discovery

Clinical Cancer Research

Volumn 14, Issue 19, 2008, Pages 6246-6252

  Hu, Shen ^a,e   Arellano, Martha ^a   Boontheung, Pinmanee ^b   Wang, Jianghua ^a   Zhou, Hui ^a   Jiang, Jiang ^a   Elashoff, David ^d   Wei, Roger ^a   Loo, Joseph A ^b   Wong, David T ^a,b,c,e  

^a School of Dentistry   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c University of California   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; POLYMER; TUMOR MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEOMICS; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; ROC CURVE; SALIVA ANALYSIS; SALIVARY GLAND; SQUAMOUS CELL CARCINOMA; TIME OF FLIGHT MASS SPECTROMETRY; CHEMISTRY; IMMUNOASSAY; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUTH TUMOR; SALIVA; SENSITIVITY AND SPECIFICITY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADULT; BIOLOGICAL MARKERS; CARCINOMA, SQUAMOUS CELL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; IMMUNOASSAY; MALE; MIDDLE AGED; MOUTH NEOPLASMS; POLYMERS; PROTEOMICS; SALIVA; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 58149156457     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-5037     Document Type: Article

References (50)

1. Greenlee RT, Murray T, Bolden S, et al. Cancer tatistics, 2000. CA Cancer J Clin 2000;50:7-33.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
3. Cancer facts and figures 2006. Atlanta: American Cancer Society; 2006.
4. Lippman SM, Hong WK. Molecular markers of the risk of oral cancer. N Engl J Med 2001;344:1323-6.
5. Vokes EE, Weichselbaum RR, Lippman SM, et al. Head and neck cancer. N Engl J Med 1993;328:184-94.
6. Fliss MS, Usadel H, Caballero OL, et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 2000;287:2017-9.
7. Sidransky D. Nucleic acid-based methods for the detection of cancer. Science 1997;278:1054-9.
8. 6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients. Cancer Res 2001;61:939-42.
9. Righini CA, de Fraipont F, Timsit JF, et al. Tumor-specific methylation in saliva: a promising biomarker for early detection of head and neck cancer recurrence. Clin Cancer Res 2007;13:1179-85.
10. Li Y, St John MAR, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res 2004;10:8442-50.
11. Franzmann EJ, Reategui EP, Pedroso F, et al. Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev 2007;16:1348-55.
12. Nagler R, Bahar G, Shpitzer T, et al. Concomitant analysis of salivary tumor markers - a new diagnostic tool for oral cancer. Clin Cancer Res 2006;12:3979-84.
13. Tavassoli M, Brunel N, Maher R, et al. p53 antibodies in the saliva of patients with squamous cell carcinoma of the oral cavity. Int J Cancer 1998;78:390-1.
14. Xie H, Onsongo G, Popko J, et al. Proteomics analysis of cells in whole saliva from oral cancer patients via value-added three-dimensional peptide fractionation and tandem mass spectrometry. Mol Cell Proteomics 2008;7:486-98.
15. Mavazesh M. Methods for collecting saliva. Ann N Y Acad Sci 1993;694:72-7.
16. Lippman SM, Sudbo J, Hong WK. Oral cancer prevention and the evolution of molecular-targeted drug development. J Clin Oncol 2005;23:346-56.
17. Chen J, He QY, Yuen AP, Chiu JF. Proteomics of buccal squamous cell carcinoma: the involvement of multiple pathways in tumorigenesis. Proteomics 2004;4:2465-75.
18. Hu S, Li Y, Wang J, et al. Human saliva proteome and transcriptome. J Dent Res 2006;85:1129-33.
19. Hu S, Loo JA, Wong DT. Human saliva proteome analysis and disease biomarker discovery. Expert Rev Proteomics 2007;4:531-8.
20. Hu S, Xie Y, Ramachandran P, et al. Large-scale identification of proteins in human salivary proteome by liquid chromatography/mass spectrometry and two-dimensional gel electrophoresis-mass spectrometry. Proteomics 2005;5:1714- 28.
21. Ramachandran P, Boontheung P, Xie Y, et al. Identification of N-linked glycoproteins in human saliva by glycoprotein capture and mass spectrometry. J Proteome Res 2006;5:1493-503.
22. Denny P, Hagen FK, Hardt M, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res 2008;7:1994-2006.
23. Ryu OH, Atkinson JC, Hoehn GT, et al. Identification of parotid salivary biomarkers in Sjogren's syndrome by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry and two-dimensional difference gel electrophoresis. Rheumatology 2006;45:1077-86.
24. Hu S, Wang J, Meijer J, et al. Salivary proteomic and genomic biomarkers for primary Sjogren's Syndrome. Arthritis Rheum 2007;56:3588-600.
25. Schirmer EC, Florens L, Guan T, et al. Nuclear membrane proteins with potential disease links found by subtractive proteomics. Science 2003;301:1380-2.
26. Liu H, Sadygov RG, Yates JR. A model for random sampling and estimation of relative protein abundance in shotgun proteomics. Anal Chem 2004;76:4193-201.
27. Dieguez-Acuna FJ, Gerber SA, Kodama S, et al. Characterization of mouse spleen cells by subtractive proteomics. Mol Cell Proteomics 2005;4:1459-70.
28. Zybailov B, Coleman MK, Florens L, et al. Correlation of relative abundance ratios derived from peptide ion chromatograms and spectrum counting for quantitative proteomic analysis using stable isotope labeling. Anal Chem 2005;77:6218-24.
29. Veenstra TD. Global and targeted quantitative proteomics for biomarker discovery. J Chromatogr B Analyt Technol Biomed Life Sci 2007;847:3-11.
30. Kaur J, Kaur J, Ralhan R. Induction of apoptosis by abrogation of HSP70 expression in human oral cancer cells. Int J Cancer 2000;85:1-5.
31. Vimalachandran D, Greenhalf W, Thompson C, et al. High nuclear S100A6 (Calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 2005;65:3218-25.
32. Chen CH, Tsai TL, Yang YS, et al. Studies of the serum HER-2/neu and squamous cell carcinoma-related antigen expression in patients with oral squamous cell carcinoma. J Oral Pathol Med 2007;36:83-7.
33. Park S-H, Chung YM, Lee Y-S, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000;6:4915-20.
34. Hu S, Yu T, Xie Y, et al. Discovery of oral fluid biomarkers for human oral cancer by mass spectrometry. Cancer Genomics Proteomics 2007;4:55-64.
35. Wong P, Taillefer D, Lakins J, et al. Molecular characterization of human TRPM-2/clusterin, a gene associated with spermmaturation, apoptosis and neurodegeneration. Eur J Biochem 1994;221:917-25.
36. Zhang LY, Ying WT, Mao YS, et al. Loss of cluster in both in serum and tissue correlates with the tumorigenesis of esophageal squamous cell carcinoma via proteomics approaches. World J Gastroenterol 2003;9:650-4.
37. Scaltriti M, Brausi M, Amorosi A, et al. Clusterin (SGP-2, ApoJ) expression is downregulated in low- and high-grade human prostate cancer. Int J Cancer 2004;108:23-30.
38. Park YP, Choi SC, Kim JH, et al. Up-regulation of Mac-2 binding protein by hTERT in gastric cancer. Int J Cancer 2007;120:813-20.
39. Ulmer TA, Keeler V, Loh L, et al. Tumor-associated antigen 90K/Mac-2-binding protein: possible role in colon cancer. J Cell Biochem 2006;98:1351-66.
40. Marchetti A, Tinari N, Buttitta F, et al. Expression of 90K (Mac-2 BP) correlates with distant metastasis and predicts survival in stage Inon-small cell lung cancer patients. Cancer Res 2002;62:2535-9.
41. Wu CC, Chien KY, Tsang NM, et al. Cancer cell-secreted proteomes as a basis for searching potential tumor markers: nasopharyngeal carcinoma as a model. Proteomics 2005;5:3173- 82.
42. He QY, Chen J, Kung HF, et al. Identification of tumor-associated proteins in oral tongue squamous cell carcinoma by proteomics. Proteomics 2004;4:271-8.
43. Ravindranath NM, Shuler C. Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:231- 9.
44. Huang CM, Ananthaswamy HN, Barnes S, et al. Mass spectrometric proteomics profiles of in vivo tumor secretomes: capillary ultrafiltration sampling of regressive tumor masses. Proteomics 2006;6:6107-16.
45. McEligot AJ, Yang S, Meyskens JFL. Redox regulation by intrinsic species and extrinsic nutrients in normal and cancer cells. Annu Rev Nutr 2005;25:261-95.
46. Henson DE, Srivastava S, Kramer BS. Molecular and genetic targets in early detection. Curr Opin Oncol 1999;11:419-25.
47. Pepe MS, Etzioni R, Feng Z, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
48. Li Y, Denny P, Ho CM, et al. The Oral Fluid MEMS/ NEMS Chip (OFMNC): diagnostic and translational applications. Adv Dent Res 2005;18:3-5.
49. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. J Am Dent Assoc 2006;137:313-21.
50. Lingen MW. Oral cancer screening aids: where is the science? Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2007;103:153-4.